TRYPF

Tryp Therapeutics Inc. is a Canada-based clinical stage pharmaceutical company. The Company is focused on developing compounds for the treatment of rare or orphan diseases and other diseases with unmet medical needs. Its lead development program, psilocybinfor-neuropsychiatry (PFN) program, is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. The indication for its PFN program is fibromyalgia. The Company is also evaluating additional indications for its PFN program, including hyperphagia in Prader Willi syndrome (PWS) and other neuropsychiatric-based chronic pain conditions and eating disorders. The Company is also engaged in developing a formulation of razoxane for the treatment of soft tissue sarcomas.